Osteoporosis screening, prevention, treatment and switching between therapies

Switching between osteoporosis medicines is not a simple handover, it can determine whether treatment gains are protected or fracture risk rebounds. This article equips pharmacists to recognise when therapy switching matters most, particularly with denosumab, and to support safe, timely decisions regarding osteoporosis screening, prevention and treatment. By Dr Treasure McGuire, Assistant Director of Pharmacy,